NEWS & EVENTS

 

GammaDelta Therapeutics Q&A

 
GammaDelta Therapeutics Q&A

17 November 2017

Founded in 2016 with the help of venture capital firm Abingworth and support from Cancer Research Technology Limited, King’s College London and the Francis Crick Institute, London-based GammaDelta Therapeutics “GammaDelta” is a young and ambitious immunotherapy company with an exciting future ahead.

Mewburn Ellis Partner, Emily Hayes, held a Q&A session with Raj Mehta, Director of IP, Alliance Management and BD at GammaDelta, to talk about the future of the business and the role of IP.

Read the full article: GammaDelta Q&A